In vivo effects of contrast media on coronary thrombolysis
Sorin Pislaru, MD, PhD*  ,
Cristina Pislaru, MD*,
Monika Szilard, MD*,
Jef Arnout, PhD and
Frans Van de Werf, MD, PhD, FACC*
* Department of Cardiology, University Hospitals Leuven, Leuven, Belgium
"Carol Davila" University of Medicine, Bucharest, Romania
Center for Molecular and Vascular Biology, University of Leuven, Leuven, Belgium
View larger version (50K):
[in a new window]
|
Figure 1 Strip chart (maximum compression). Top curve = ECG lead II; middle curve = aortic pressure; bottom curve = coronary flow. The experimental setup comprised a 90-min occlusion period followed by thrombolysis with recombinant tissue plasminogen activator, alteplase (bolus and 30-min infusion) and co-therapy with aspirin (bolus) and heparin (bolus and 2-h infusion). Contrast media (CM) or placebo were administered intracoronary, starting 20 min before thrombolysis. The events identified by strip chart analysis (occlusion, reperfusion, peak hyperemic flow and cyclic flow) were used for the calculation of time parameters.
|
|
View larger version (41K):
[in a new window]
|
Figure 2 Schematic representation of the patency status of the LAD coronary artery. Black squares = zero flow; striped squares = periods with cyclic flows; open (white) squares = periods with optimal coronary perfusion. The time-point at which the peak hyperemic flow occurred (at the beginning of optimal reperfusion) is marked with an X. r-tPA = recombinant tissue plasminogen activator, alteplase.
|
|
|
